ResMed PT receives Investment Bank Analyst Rating Update
ResMed (RMD) reported Q2 EPS of $1.66, $0.06 better than the analyst estimate of $1.60. Revenue for the quarter came in at $1.03 million versus the consensus estimate of $990.85...
Investing.com - ResMed (NYSE: RMD) reported second quarter EPS of $1.66, $0.06 better than the analyst estimate of $1.60. Revenue for the quarter came in at $1.03M versus the...
S&P 500 EPS growth for Q2 is set to come in at 6.7%, the lowest level since Q4 2020 Some highly anticipated names reported last week, with upbeat results from SBUX, ABNB,...
The people who buy and sell stocks for a living seemed to panic in mid-June. The way they saw things, the Federal Reserve was suddenly signaling it might start raising interest...
ResMed Inc. is a holding company. The Company, through its subsidiaries, is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep-disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. It also offers software solutions for a variety of out-of-hospital care providers. The Company has two segments: Sleep and Respiratory Care and the Software-as-a-Service. Sleep apnea includes obstructive sleep apnea and other respiratory disorders that occur during sleep. Its cloud-based digital health applications, along with its devices, are designed to provide connected care to improve patient outcomes. The Company's portfolio of products includes ventilation devices, diagnostic products, mask systems, headgear and other accessories, dental devices and cloud-based software informatics solutions.
|Average||257.57 (+16.31% Upside)|
|No. of Analysts||7|